HomeCompareAPEN vs EQR

APEN vs EQR: Dividend Comparison 2026

APEN yields 20.00% · EQR yields 5.87%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 APEN wins by $25.2K in total portfolio value
10 years
APEN
APEN
● Live price
20.00%
Share price
$10.00
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$73.0K
Annual income
$6,738.96
Full APEN calculator →
EQR
EQR
● Live price
5.87%
Share price
$59.15
Annual div
$3.47
5Y div CAGR
15.8%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$47.8K
Annual income
$5,475.61
Full EQR calculator →

Portfolio growth — APEN vs EQR

📍 APEN pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodAPENEQR
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, APEN + EQR cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
APEN pays
EQR pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

APEN
Annual income on $10K today (after 15% tax)
$1,700.00/yr
After 10yr DRIP, annual income (after tax)
$5,728.12/yr
EQR
Annual income on $10K today (after 15% tax)
$499.01/yr
After 10yr DRIP, annual income (after tax)
$4,654.27/yr
At 15% tax rate, APEN beats the other by $1,073.85/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of APEN + EQR for your $10,000?

APEN: 50%EQR: 50%
100% EQR50/50100% APEN
Portfolio after 10yr
$60.4K
Annual income
$6,107.28/yr
Blended yield
10.11%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on EQR right now

APEN
Analyst Ratings
4
Buy
4
Hold
1
Sell
Consensus: Buy
Price Target
$9.50
-5.0% upside vs current
Range: $9.00 — $10.00
Altman Z
0.7
Piotroski
3/9
EQR
Analyst Ratings
16
Buy
28
Hold
2
Sell
Consensus: Hold
Price Target
$70.35
+18.9% upside vs current
Range: $63.00 — $78.50
Altman Z
1.8
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

APEN buys
0
EQR buys
0
No recent congressional trades found for APEN or EQR in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricAPENEQR
Forward yield20.00%5.87%
Annual dividend / share$2.00$3.47
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%15.8%
Portfolio after 10y$73.0K$47.8K
Annual income after 10y$6,738.96$5,475.61
Total dividends collected$41.5K$23.0K
Payment frequencyquarterlyquarterly
SectorStockREIT
Analyst consensusBuyHold
Analyst price target$9.50$70.35

Year-by-year: APEN vs EQR ($10,000, DRIP)

YearAPEN PortfolioAPEN Income/yrEQR PortfolioEQR Income/yrGap
1← crossover$12,700$2,000.00$11,380$679.82+$1.3KAPEN
2$15,963$2,373.83$13,014$837.25+$2.9KAPEN
3$19,869$2,788.51$14,961$1,036.20+$4.9KAPEN
4$24,503$3,243.76$17,297$1,289.22+$7.2KAPEN
5$29,957$3,738.69$20,121$1,613.15+$9.8KAPEN
6$36,326$4,271.82$23,561$2,030.84+$12.8KAPEN
7$43,710$4,841.12$27,783$2,573.54+$15.9KAPEN
8$52,214$5,444.08$33,013$3,284.39+$19.2KAPEN
9$61,947$6,077.78$39,547$4,223.51+$22.4KAPEN
10$73,022$6,738.96$47,791$5,475.61+$25.2KAPEN

APEN vs EQR: Complete Analysis 2026

APENStock

Apollo Endosurgery, Inc., a medical technology company, focuses on the design, development, and commercialization of medical devices. The company offers OverStitch and OverStitch Sx Endoscopic Suturing Systems that enable advanced endoscopic procedures by allowing physicians to sutures and secure the approximation of tissue through a flexible endoscope. It also provides Orbera, an intragastric balloon system that reduces stomach capacity causing patients to consume less following the procedure, as well as delays gastric content emptying under the Orbera Intragastric Balloon System, BIB, and Orbera365 Managed Weight Loss System brands. Additionally, the company offers X-Tack Endoscopic HeliX Tacking System, a suture-based device for closing and healing defects in the lower and upper gastrointestinal tract. The company sells its products to medical services providers; and hospitals, outpatient surgical centers, clinics, and physicians in the United States, Australia, Costa Rica, and other European countries. Apollo Endosurgery, Inc. was founded in 2005 and is headquartered in Austin, Texas.

Full APEN Calculator →

EQRREIT

Equity Residential is committed to creating communities where people thrive. The Company, a member of the S&P 500, is focused on the acquisition, development and management of residential properties located in and around dynamic cities that attract high quality long-term renters. Equity Residential owns or has investments in 305 properties consisting of 78,568 apartment units, located in Boston, New York, Washington, D.C., Seattle, San Francisco, Southern California and Denver.

Full EQR Calculator →
📬

Get this APEN vs EQR comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

APEN vs SCHDAPEN vs JEPIAPEN vs OAPEN vs KOAPEN vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.